In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA center structure may be ripe for reorganization, deputy commissioner suggests.

This article was originally published in The Tan Sheet

Executive Summary

FDA CENTER STRUCTURE REVISION SHOULD BE CONSIDERED, DEPUTY COMMISSIONER Mary Pendergast suggested during a May 7 Food & Drug Law Institute meeting in Washington, D.C. "As technology becomes a seamless web, and not the old chemical drugs, biological drugs and mechanical things, as we realize that there is a seamless web of products out there, we have to continue to work to be a seamless web of an agency," Pendergast said. The upcoming appointment of a new FDA commissioner presents a logical opportunity for another review of FDA's structural lay-out.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts